Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Transplantation of endothelial progenitor cells attenuates pulmonary fibrosis via IFITM3-containing exosomes
Ying-Wei Lan, Jonathan Do, Wen Gao, Zicheng Deng, Xiaomei Xia, Enhong Li, Jillian Kash, Gautam Verma, Angara Sureshbabu, Kenneth S. Knox, Ross M. Bremner, Nicholas E. Banovich, Vladimir V. Kalinichenko, Tanya V. Kalin
Ying-Wei Lan, Jonathan Do, Wen Gao, Zicheng Deng, Xiaomei Xia, Enhong Li, Jillian Kash, Gautam Verma, Angara Sureshbabu, Kenneth S. Knox, Ross M. Bremner, Nicholas E. Banovich, Vladimir V. Kalinichenko, Tanya V. Kalin
View: Text | PDF
Research Article Pulmonology Vascular biology

Transplantation of endothelial progenitor cells attenuates pulmonary fibrosis via IFITM3-containing exosomes

  • Text
  • PDF
Abstract

Endothelial progenitor cells (EPCs) are critical for vascular regeneration after injury. However, their role in pulmonary fibrosis (PF) remains unclear. Here, we identified a previously unrecognized population of lung capillary EPCs coexpressing c-KIT and FOXF1 (capEPCs) in adult human and mouse lungs. capEPCs were significantly reduced in lungs from patients with PF and in bleomycin-injured mice, implicating loss of this regenerative endothelial population in disease pathogenesis. Transplantation of donor capEPCs attenuated experimental PF, improved survival, reduced collagen deposition, and restored lung function. Donor capEPCs engrafted into the lung microcirculation of bleomycin-injured mice. Single-cell RNA sequencing identified interferon-induced transmembrane protein 3 as a highly enriched transcript in capEPCs. Conditioned media from IFITM3-overexpressing EPCs or recombinant IFITM3 enhanced endothelial proliferation and angiogenesis while suppressing TGF-β1–induced fibroblast activation in vitro. IFITM3 was found in capEPC-derived exosomes. Treatment with IFITM3-containing exosomes recapitulated the therapeutic effects of capEPC transplantation by improving endothelial function, inhibiting fibroblast activation, increasing animal survival, reducing lung fibrosis, and restoring lung function. Together these findings identified capEPC deficiency as a feature of PF and demonstrated that IFITM3-containing exosomes promoted vascular repair. Restoration of capEPC regenerative function or delivery of IFITM3-enriched exosomes may represent a promising therapeutic strategy for human PF.

Authors

Ying-Wei Lan, Jonathan Do, Wen Gao, Zicheng Deng, Xiaomei Xia, Enhong Li, Jillian Kash, Gautam Verma, Angara Sureshbabu, Kenneth S. Knox, Ross M. Bremner, Nicholas E. Banovich, Vladimir V. Kalinichenko, Tanya V. Kalin

×

Figure 6

Ifitm3 is a direct transcriptional target of FOXF1.

Options: View larger image (or click on image) Download as PowerPoint

Ifitm3 is a direct transcriptional target of FOXF1.
(A) scRNA-seq of ad...
(A) scRNA-seq of adult mouse lungs shows Foxf1 mRNA in capEPCs (n = 312 cells) compared with Foxf1–Kit+ ECs (n = 70 cells). (B) Differentially expressed genes between capEPCs and Foxf1–Kit+ ECs show upregulation of Ifitm3 in capEPCs. (C) qRT-PCR of FACS-sorted lung ECs shows higher Foxf1 and Ifitm3 mRNA levels in capEPCs (n = 4). (D) Dot plot analysis of human lung scRNA-seq data (GSE227136) demonstrates coexpression of IFITM3 and FOXF1 in capEPCs. (E) Quantitative proteomic analysis of bronchoalveolar lavage fluid (BALF) from donor controls (n = 5) and patients with idiopathic pulmonary fibrosis (IPF; n = 4) demonstrates decreased IFITM3 protein levels in IPF BALF samples. Data were extracted and reanalyzed from a previously published BALF proteomics dataset (31). A 2-tailed Mann-Whitney test was used. (F and G) siRNA-mediated knockdown of Foxf1 in Kit+ lung ECs decreased Foxf1 and Ifitm3 mRNA expression (F; control, n = 4; siFoxf1, n = 3), and conditioned medium from these cells reduced endothelial tube formation in vitro (G; n = 4 per group). Scale bars in G: 100 μm. (H) ChIP-seq analysis (GSE77951) shows FOXF1 binding to the Ifitm3 promoter region. (I) Luciferase (Luc) assay demonstrates increased transcription from Ifitm3 promoter region (–267/+0 bp) in the presence of FOXF1 (n = 4). Data are presented as mean ± SD. Unpaired 2-tailed t tests were used. *P < 0.05, **P < 0.01, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts